Apixaban in Pulmonary Embolism Treatment

Introduction to Apixaban

• The American College of Cardiology recommends apixaban as a first-line treatment option for pulmonary embolism, with a dosing regimen of 10 mg twice daily for 7 days followed by 5 mg twice daily, demonstrating non-inferiority to conventional therapy with significantly lower bleeding risk 1

Dosing and Efficacy

• The European Society of Cardiology suggests an initial treatment of 10 mg twice daily for the first 7 days, followed by maintenance therapy of 5 mg twice daily for at least 3 months, with apixaban being non-inferior to conventional therapy for preventing recurrent VTE or VTE-related death 1
• Apixaban has a significantly lower major bleeding rate compared to conventional therapy, with a relative risk of 0.31 (95% CI 0.17-0.55; p<0.001) 1

Special Populations

• For cancer patients, the American College of Chest Physicians suggests using direct oral anticoagulants like apixaban over low molecular weight heparin, with apixaban being non-inferior to dalteparin for cancer-associated VTE without increased bleeding risk 3

Duration of Therapy

• The American College of Chest Physicians recommends a minimum of 3 months of treatment for most patients with PE, with extended anticoagulation considered for unprovoked PE or those with persistent risk factors 3